2 Space Stocks That Could Double in 2027 (Hint: Neither of Them Is SpaceX)

Redwire is expanding its Huntsville campus by 164,000 square feet to support space infrastructure and defense manufacturing, positioning its diversified satellite, autonomous-system, and counter-drone operations as the steadier space-sector investment. Rocket Lab offers higher upside but greater execution risk, with its reusable medium-lift Neutron rocket targeted for a first launch in 2027 and its planned Iridium acquisition expected to close in mid-2027 pending regulatory approval. The article argues both companies could potentially double by 2027 as global space and defense spending grows, though Rocket Lab's thesis depends heavily on Neutron's successful launch and Iridium integration.

Analysis

The key valuation distinction is backlog quality versus narrative duration. RDW’s defense-adjacent hardware mix can support a higher revenue multiple only if new Huntsville capacity converts into funded programs and utilization rises; otherwise, the expansion creates fixed-cost absorption risk before revenue arrives. Its more relevant competitive set is not launch peers but defense-electronics and satellite-component suppliers such as L3Harris (LHX), RTX and Kratos (KTOS), where procurement-cycle delays can matter more than headline space spending.

RKLB’s upside is increasingly a capital-allocation and execution trade, not simply a launch-market trade. Neutron’s first-flight milestone may re-rate the equity in the next 6-12 months, but commercial cadence, payload reliability and unit economics—not a demonstration launch—determine whether the program earns an enduring medium-lift valuation. A transaction involving IRDM would add recurring service revenue but also introduces regulatory, financing, integration and potential equity-dilution risks; the claimed deal terms, pro forma leverage, exchange ratio and required approvals must be independently verified before treating it as investable information.

The consensus likely underweights how much a successful vertically integrated competitor pressures satellite primes and component vendors: RKLB capturing spacecraft manufacturing plus launch can compress addressable content for standalone suppliers. Conversely, the market may be overpaying today for optionality if government awards remain prototype-heavy rather than converting to production contracts. Near-term sentiment can stay constructive, but the 6-18 month outcome hinges on cash burn and funded backlog conversion rather than sector enthusiasm.

Falsification points: for RDW, watch quarterly book-to-bill below 1.0x, gross-margin deterioration as capacity ramps, or a defense-program funding delay. For RKLB, reassess on any Neutron schedule slip beyond 2027, material increase in estimated development spend, Electron reliability issue, or acquisition financing that materially raises net leverage/dilution versus disclosed terms.

Key Decisions for Investors

• Maintain RDW as the lower-beta space/defense expression only after confirming two consecutive quarters of book-to-bill above 1.0x and stable-to-improving gross margin; size modestly given small-cap liquidity. Target a 6-12 month rerating on backlog conversion, with a stop/review trigger on margin compression or delayed facility utilization.
• Do not chase RKLB on launch-date headlines. Establish a staged long over 3-6 months only if Neutron development milestones remain on schedule and annual cash-burn guidance does not rise materially; treat a first launch as a tradable catalyst, not proof of commercial economics.
• For a higher-conviction relative-value expression, consider long RDW / short a basket of higher-multiple, launch-dependent space exposure including RKLB only if RKLB materially outperforms into Neutron enthusiasm. The thesis is RDW’s procurement-backed revenue should prove less duration-sensitive; cover if RDW book-to-bill weakens or RKLB secures binding multi-launch medium-lift contracts.
• Set an immediate verification alert on the purported RKLB-IRDM transaction: confirm SEC filings, purchase consideration, financing sources, regulatory timetable and pro forma leverage. Until those data are available, no IRDM merger-arbitrage or RKLB acquisition-synergy position is recommended; an unverified transaction claim is itself a material information-quality risk.